Inhibitory and morphological effects of several antifungal agents on three types of Candida albicans morphological mutants

REFERENCES

• Bennet J.E. Developing drugs for the deep mycoes: a short history. New Strategies in Fungal Disease, J.E. Bennet, R.J. Hay, P.K. Peterson. Churchill Livingstone, Edinburgh 1992; 3–12, In
   Google Scholar
• Borgers M. Mechanism of action of antifungal drugs, with special reference to the imidazole derivatives. Reviews of Infectious Diseases 1980; 2: 520–534
   PubMedGoogle Scholar
• Borgers M. Ultrastructural correlates of antimycotic treatment. Current Topics in Medical Mycology, M.R. Mcginnis. Springer-Verlag, New York 1988; 2: 1–39, In
   Google Scholar
• Bozzola J.J., Mehta R.J., Nisbet L.J., Valenta J.R. The effect of aculeacin A and papulacandin B on morphology and cell wall ultrastructure in Candida albicans. Canadian Journal of Microbiology 1984; 30: 857–863
   PubMed Web of Science ®Google Scholar
• Cannon R.D. Isolation of a mycelial mutant of Candida albicans. Journal of General Microbiology 1986; 132: 2405–2407
   PubMedGoogle Scholar
• Gil C., Pomés R., Nombela C. A complementation analysis by parasexual recombination of Candida albicans morphological mutants. Journal of General Microbiology 1988; 134: 1587–1595
   PubMedGoogle Scholar
• Gil C., Pomés R., Nombela C. Isolation and characterization of Candida albicans morphological mutants derepressed for the formation of filamentous hypha-type structures. Journal of Bacteriology 1990; 172: 2384–2391
   PubMed Web of Science ®Google Scholar
• Gordee R.S., Zeckner D.J., Alborn W.E. Action of LY 121019 on Candida albicans cell wall biosynthesis. Program and Abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy, New York 1987. American Society for Microbiology, Washington, DC 1987; 267–267, In Abstract 977
   Google Scholar
• Hector R.F. Compounds active against cell walls of medically important fungi. Clinical Microbiology Reviews 1993; 6: 1–21
   PubMed Web of Science ®Google Scholar
• Herreros E., García-Sáez M.I., Nombela C., Sánchez M. A reorganized Candida albicans DNA sequence promoting homologous non-integrative genetic transformation. Molecular Microbiology 1992; 6: 3567–3574
   PubMed Web of Science ®Google Scholar
• Johnson E.M., Richardson M.D., Warnock D.W. Effect of imidazole antifungals on the development of germ tubes by strains of Candida albicans. Journal of Antimicrobial Chemotherapy 1983; 12: 303–316
   PubMed Web of Science ®Google Scholar
• Lee K.L., Buckley H.R., Campbell C.C. An amino acid liquid synthetic medium for the development of mycelial and yeast forms of Candida albicans. Sabouraudia 1975; 13: 148–153
   PubMedGoogle Scholar
• Niimi M., Kamiyama A., Tokunaga M., Tokunaga J., Nakayama H. Germ tube-forming cells of Candida albicans are more susceptible to clotrimazole-induced killing than yeast cells. Sabouraudia: Journal of Medical and Veterinary Mycology 1985; 23: 63–68
   Google Scholar
• Nombela C., Pla J., Herreros E., Gil C., Molina M., Sanchez M. Novel targets for antifungal drugs. New Strategies in Fungal Disease, J.E. Bennet, R.J. Hay, P.K. Peterson. Churchill Livingstone, Edinburgh 1992; 117–129, In
   Google Scholar
• Nombela C., Pomés R., Gil C. Protoplasts fusion hybrids from Candida albicans morphological mutants. CRC Critical Reviews in Microbiology 1987; 15: 79–85
   Web of Science ®Google Scholar
• Nombela C., Pomés R., Gil C., Herreros E., Sánchez M. Genetics of pathogenic fungi: Candida albicans. Revista Ibérica de Micología 1989; 6: 47–53
   Google Scholar
• Odds F.C. Candida and Candidosis. A Review and Bibliography2nd edn. Bailliére. Tindall, London 1988
   Google Scholar
• Pomés R., Gil C., Nombela C. Genetic analysis of Candida albicans morphological mutants. Journal of General Microbiology 1985; 131: 2107–2113
   PubMedGoogle Scholar
• Ryley J.F., Rathmell W.G. Discovery of antifungal agents. In vitro and in vivo testing. Mode of Action of Antifungal Agents, A.P.J. Trinci, J.F. Ryley. Cambridge University Press, Cambridge 1984; 63–87, In
   Google Scholar
• Shadomy S., Espinel-Ingroff A., Cartwright R.Y. Laboratory studies with antifungal agents: susceptibility tests and bioassays. Manual of Clinical Microbiology4th edn., E.H. Lennette, A. Balows, W.J. Hausler, H.J. Shadomy. American Society for Microbiology, Washington, DC 1985; 991–999, In
   Google Scholar
• Smith K.R., Lank K.M., Dismukes W.E., Cobbs C.G. In vitro comparison of cilofungin alone and in combination with other antifungal agents against clinical isolates of Candida species. European Journal of Clinical Microbiology and Infectious Diseases 1991; 10: 588–592
   PubMed Web of Science ®Google Scholar
• Surarit R., Shepherd M.G. The effects of azole and polyene antifungals on the plasma membrane enzymes of Candida albicans. Journal of Medical and Veterinary Mycology 1987; 25: 403–413
   PubMedGoogle Scholar
• Taft C.S., Stark T., Selitrennikoff C.P. Cilofungin (LY 121019) inhibits Candida albicans (1,3)-β-d-glucan synthase activity. Antimicrobial Agents and Chemotherapy 1988; 32: 1901–1903
   PubMed Web of Science ®Google Scholar
• Vanden Bossche H. Mode of action of antifungal drugs: focus on azoles. International Journal of Experimental and Clinical Chemotherapy 1990; 2(Suppl 1)25–36
   Google Scholar
• Vanden Bossche H., Willensens G., Marichal P. Anti-Candida drugs. The biochemical basis for their activity. CRC Critical Reviews in Microbiology 1987; 15: 57–72
   Google Scholar